Spectral analysis applied to hepatobiliary dynamic scintigraphy with 99Tcm-N-pyridoxyl-5-methyltryptophan.
This study was performed to evaluate the application of spectral analysis (SA) to hepatobiliary dynamic scintigraphy with 99Tcm-N-pyridoxyl-5-methyltryptophan (99Tcm-PMT) in 82 patients with a wide range of liver function, and to compare it with compartment analysis (CA) and deconvolution analysis (DA). The rate of uptake of PMT by the liver from the blood (k1) obtained by SA (y, min-1) agreed well with the k1 value obtained using CA (x, min-1) (y = 1.079x + 0.000, r = 0.993, standard error of the estimate (S.E.E.) = 0.042 min-1). The mean residence time (MRT) of PMT in the liver obtained by SA (y, min) also agreed well with the MRT value obtained by DA (x, min) (y = 1.036x - 0.759, r = 0.967, S.E.E.-1.014 min) and that obtained by CA (x, min) (y = 0.859x + 1.006, r = 0.931, S.E.E. = 1.428 min). The fraction of the measured blood activity superimposed on the true liver activity (f) obtained by SA (y) correlated well with the f value obtained by CA (x) (y = 1.168x - 0.004, r = 0.924, S.E.E. = 0.043). We conclude that the application of SA to hepatobiliary dynamic scintigraphy with PMT appears to be useful in evaluating the functional status of the liver, since it facilitates the interpretation of the kinetic behaviour of PMT in the liver and allows us to extract quantitative parameters corresponding to those obtained by CA or DA.
Murase
K
K
Department of Radiology, Ehime University School of Medicine, Japan.
Tsuda
T
T
Mochizuki
T
T
Tanada
S
S
Ikezoe
J
J
D001659:Biliary Tract / Q000000981:diagnostic imaging* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000000981:diagnostic imaging* / Q000503:physiopathology; D008107:Liver Diseases / Q000000981:diagnostic imaging* / Q000503:physiopathology; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008954:Models, Biological; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011730:Pyridoxal / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012044:Regression Analysis; D014018:Tissue Distribution; D014364:Tryptophan / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C038081:technetium Tc 99m pyridoxyl-5-methyltryptophan; D011730:Pyridoxal; D014364:Tryptophan